Bladder cancer biomarkers

Current developments and future implementation

Alonso Alvarez, Vinata B Lokeshwar

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Bladder cancer biomarker development has advanced significantly over the last decade, but has not yet been able to make a significant impact in the diagnosis and management of the disease. Many available markers are suitable, but do not meet the expectations of physicians and patients. Patients do not want to compromise accuracy in diagnosing bladder cancer for less-invasive tests. The review highlights the latest developments in bladder cancer biomarkers, including markers developed over the last year, and comments on the high standards placed on these markers which have delayed their widespread implementation into the urologic field. RECENT FINDINGS: New markers described in the last year include soluble Fas, urothelial carcinoma-associated 1 and human chorionic gonadotropin β type II genes. The latter two markers represent the contribution of genomic technology to this field. Also described are updates to known markers, including long-term follow-up of hematuria screening, recent studies in DNA methylation for bladder cancer diagnosis and patient perspectives on bladder tumor markers. SUMMARY: Biomarkers for bladder cancer have been intensively scrutinized over the last decade, but despite new findings and good performance characteristics, they are currently not accepted in clinical practice.

Original languageEnglish (US)
Pages (from-to)341-346
Number of pages6
JournalCurrent Opinion in Urology
Volume17
Issue number5
DOIs
StatePublished - Sep 1 2007

Fingerprint

Tumor Biomarkers
Urinary Bladder Neoplasms
Hematuria
DNA Methylation
Chorionic Gonadotropin
Disease Management
Biomarkers
Technology
Carcinoma
Physicians
Genes

Keywords

  • Bladder cancer
  • Diagnosis
  • Surveillance
  • Tumor markers
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Bladder cancer biomarkers : Current developments and future implementation. / Alvarez, Alonso; Lokeshwar, Vinata B.

In: Current Opinion in Urology, Vol. 17, No. 5, 01.09.2007, p. 341-346.

Research output: Contribution to journalReview article

@article{089e61d3c279480eb2afdd0a2fea55fc,
title = "Bladder cancer biomarkers: Current developments and future implementation",
abstract = "PURPOSE OF REVIEW: Bladder cancer biomarker development has advanced significantly over the last decade, but has not yet been able to make a significant impact in the diagnosis and management of the disease. Many available markers are suitable, but do not meet the expectations of physicians and patients. Patients do not want to compromise accuracy in diagnosing bladder cancer for less-invasive tests. The review highlights the latest developments in bladder cancer biomarkers, including markers developed over the last year, and comments on the high standards placed on these markers which have delayed their widespread implementation into the urologic field. RECENT FINDINGS: New markers described in the last year include soluble Fas, urothelial carcinoma-associated 1 and human chorionic gonadotropin β type II genes. The latter two markers represent the contribution of genomic technology to this field. Also described are updates to known markers, including long-term follow-up of hematuria screening, recent studies in DNA methylation for bladder cancer diagnosis and patient perspectives on bladder tumor markers. SUMMARY: Biomarkers for bladder cancer have been intensively scrutinized over the last decade, but despite new findings and good performance characteristics, they are currently not accepted in clinical practice.",
keywords = "Bladder cancer, Diagnosis, Surveillance, Tumor markers, Urothelial carcinoma",
author = "Alonso Alvarez and Lokeshwar, {Vinata B}",
year = "2007",
month = "9",
day = "1",
doi = "10.1097/MOU.0b013e3282c8c72b",
language = "English (US)",
volume = "17",
pages = "341--346",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Bladder cancer biomarkers

T2 - Current developments and future implementation

AU - Alvarez, Alonso

AU - Lokeshwar, Vinata B

PY - 2007/9/1

Y1 - 2007/9/1

N2 - PURPOSE OF REVIEW: Bladder cancer biomarker development has advanced significantly over the last decade, but has not yet been able to make a significant impact in the diagnosis and management of the disease. Many available markers are suitable, but do not meet the expectations of physicians and patients. Patients do not want to compromise accuracy in diagnosing bladder cancer for less-invasive tests. The review highlights the latest developments in bladder cancer biomarkers, including markers developed over the last year, and comments on the high standards placed on these markers which have delayed their widespread implementation into the urologic field. RECENT FINDINGS: New markers described in the last year include soluble Fas, urothelial carcinoma-associated 1 and human chorionic gonadotropin β type II genes. The latter two markers represent the contribution of genomic technology to this field. Also described are updates to known markers, including long-term follow-up of hematuria screening, recent studies in DNA methylation for bladder cancer diagnosis and patient perspectives on bladder tumor markers. SUMMARY: Biomarkers for bladder cancer have been intensively scrutinized over the last decade, but despite new findings and good performance characteristics, they are currently not accepted in clinical practice.

AB - PURPOSE OF REVIEW: Bladder cancer biomarker development has advanced significantly over the last decade, but has not yet been able to make a significant impact in the diagnosis and management of the disease. Many available markers are suitable, but do not meet the expectations of physicians and patients. Patients do not want to compromise accuracy in diagnosing bladder cancer for less-invasive tests. The review highlights the latest developments in bladder cancer biomarkers, including markers developed over the last year, and comments on the high standards placed on these markers which have delayed their widespread implementation into the urologic field. RECENT FINDINGS: New markers described in the last year include soluble Fas, urothelial carcinoma-associated 1 and human chorionic gonadotropin β type II genes. The latter two markers represent the contribution of genomic technology to this field. Also described are updates to known markers, including long-term follow-up of hematuria screening, recent studies in DNA methylation for bladder cancer diagnosis and patient perspectives on bladder tumor markers. SUMMARY: Biomarkers for bladder cancer have been intensively scrutinized over the last decade, but despite new findings and good performance characteristics, they are currently not accepted in clinical practice.

KW - Bladder cancer

KW - Diagnosis

KW - Surveillance

KW - Tumor markers

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=34548336951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548336951&partnerID=8YFLogxK

U2 - 10.1097/MOU.0b013e3282c8c72b

DO - 10.1097/MOU.0b013e3282c8c72b

M3 - Review article

VL - 17

SP - 341

EP - 346

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 5

ER -